Oncology & Specialty Medications

Comprehensive specialty pharmacy support for 79 oncology medications — immunotherapy, targeted therapy, CAR-T, and chemotherapy — with prior authorization, patient assistance, cost information, and free specialty delivery.

79 Medications Immunotherapy Checkpoint Inhibitors CAR-T Cell Therapy Prior Authorization Cost Information

What is an oncology specialty pharmacy?

An oncology specialty pharmacy manages oncology medications including immunotherapy, targeted therapy, CAR-T cell therapy, and chemotherapy. Services include benefits verification, prior authorization, patient assistance enrollment, and temperature-controlled specialty delivery.

How much do oncology medications cost?

Costs range from under $100/cycle for generic chemotherapy to $727,000 for one-time CAR-T therapies. Most targeted agents list at $10,000–$25,000/month (WAC). Actual patient cost is typically far lower through insurance, co-pay programs, and patient assistance. Each medication below shows approximate WAC list prices. Contact us for a free benefits verification.

All Oncology & Specialty Medications (79)

Click any medication for full details — indications, mechanism, dosage, warnings, cost, and prior authorization information.

CAR-T Cell Therapy — BCMA-directed

idecabtagene vicleucel

Abecma (idecabtagene vicleucel) is an anti-BCMA CAR-T cell therapy for relapsed or refractory multiple myeloma

~$420,000 one-time

CYP17 Inhibitor / Androgen Biosynthesi

Abiraterone Acetate

abiraterone acetate

Abiraterone acetate is a CYP17 inhibitor that blocks androgen biosynthesis in the adrenal glands, testes, and

Combination Chemotherapy Regimen

ABVD Chemotherapy Regimen

doxorubicin / bleomycin / vinblastine / dacarbaz

ABVD is a standard combination chemotherapy regimen for Hodgkin lymphoma consisting of four drugs: Adriamycin

KRAS G12C Inhibitor

Krazati (adagrasib) is a KRAS G12C inhibitor by Mirati Therapeutics (Bristol Myers Squibb) approved for adults

Gene Therapy — Adenoviral Vector (Intr

nadofaragene firadenovec-vncg

Adstiladrin (nadofaragene firadenovec-vncg) is a non-replicating adenoviral vector gene therapy instilled dire

Second-Generation EGFR / ErbB Family I

afatinib dimaleate

Gilotrif (afatinib) is a second-generation, irreversible ErbB family inhibitor by Boehringer Ingelheim approve

PARP Inhibitor + CYP17 Inhibitor Combi

niraparib and abiraterone acetate

Akeega (niraparib and abiraterone acetate) is the first FDA-approved combination of a PARP inhibitor and an an

NK1 + 5-HT3 Receptor Antagonist Combin

netupitant and palonosetron hydrochloride

Akynzeo (netupitant/palonosetron) is a fixed-dose combination of an NK1 receptor antagonist (netupitant) and a

Recombinant Interleukin-2 (IL-2) / Imm

Proleukin (aldesleukin) is recombinant interleukin-2 (IL-2) used for metastatic renal cell carcinoma and metas

Anti-CD52 Monoclonal Antibody

Lemtrada (alemtuzumab) is an anti-CD52 monoclonal antibody by Sanofi Genzyme. In oncology, alemtuzumab is used

Photosensitizing Agent / Photodynamic

Aminolevulinic Acid HCl

aminolevulinic acid hydrochloride

Aminolevulinic acid hydrochloride (Levulan Kerastick, Ameluz) is a topical photosensitizing agent used with ph

Non-Steroidal Aromatase Inhibitor

Anastrozole (brand: Arimidex) is a non-steroidal aromatase inhibitor by AstraZeneca used as first-line adjuvan

IL-15 Receptor Superagonist Complex

nogapendekin alfa inbakicept-pmln

Anktiva (nogapendekin alfa inbakicept-pmln) is an IL-15 receptor superagonist complex used in combination with

NK1 Receptor Antagonist / Antiemetic

Aprepitant (brand: Emend) is an NK1 receptor antagonist used as part of combination antiemetic therapy to prev

PD-L1 Immune Checkpoint Inhibitor

Atezolizumab is the generic/nonproprietary name for the active ingredient in Tecentriq and Tecentriq Hybreza.

KIT / PDGFRA Kinase Inhibitor

Ayvakit (avapritinib) is a KIT and PDGFRA kinase inhibitor by Blueprint Medicines. It is FDA-approved for unre

Radiopharmaceutical — Norepinephrine T

iobenguane I-131

Azedra (iobenguane I-131) is a radiopharmaceutical therapy approved for adult and pediatric patients 12 years

PD-L1 Immune Checkpoint Inhibitor

Bavencio (avelumab) is a PD-L1 immune checkpoint inhibitor by EMD Serono/Pfizer, approved for Merkel cell carc

Combination Chemotherapy Regimen — Hod

BEACOPP Regimen

bleomycin/etoposide/doxorubicin/cyclophosphamide

BEACOPP is an intensified combination chemotherapy regimen used for advanced-stage Hodgkin lymphoma. It combin

~$3,000–$8,000/cycle

BCMA-Targeted Antibody-Drug Conjugate

belantamab mafodotin-blmf

Blenrep (belantamab mafodotin-blmf) is a BCMA-targeted antibody-drug conjugate by GSK that delivers MMAF (a mi

~$16,000–$20,000/dose

HDAC Inhibitor (Histone Deacetylase In

Beleodaq (belinostat) is an HDAC inhibitor by Spectrum Pharmaceuticals approved for relapsed or refractory per

~$15,000–$20,000/cycle

Combination Chemotherapy Regimen — Ger

bleomycin/etoposide/cisplatin

BEP (Bleomycin, Etoposide, Cisplatin) is the standard first-line chemotherapy regimen for advanced germ cell t

~$500–$2,000/cycle

VEGF Inhibitor / Anti-Angiogenic Monoc

Avastin (bevacizumab) is an anti-VEGF monoclonal antibody by Genentech/Roche that inhibits tumor angiogenesis.

~$2,000–$8,000/cycle

Bispecific Antibody — HER2 × HER3 Targ

zenocutuzumab-zbco

Bizengri (zenocutuzumab-zbco) is a bispecific antibody targeting HER2 and HER3. It is FDA-approved for adult p

CD3×CD19 BiTE (Bispecific T-cell Engag

Blincyto (blinatumomab) is a CD3×CD19 BiTE (bispecific T-cell engager) antibody by Amgen. It simultaneously bi

~$45,000–$55,000/cycle

Proteasome Inhibitor

Velcade (bortezomib) is the first proteasome inhibitor approved for cancer therapy, used in multiple myeloma (

~$1,500–$5,000/cycle

CD30-Targeted Antibody-Drug Conjugate

brentuximab vedotin

Adcetris (brentuximab vedotin) is a CD30-directed antibody-drug conjugate (ADC) by Seagen/Takeda. It combines

ALK / ROS1 / EGFR Tyrosine Kinase Inhi

Alunbrig (brigatinib) is an ALK and ROS1 inhibitor by Takeda approved for adult patients with ALK-positive met

BTK Inhibitor (Bruton's Tyrosine Kinas

Calquence (acalabrutinib) is a second-generation Bruton's tyrosine kinase (BTK) inhibitor by AstraZeneca used

Fluoropyrimidine / Oral 5-FU Prodrug

Xeloda (capecitabine) is an oral fluoropyrimidine prodrug that is converted to 5-FU within tumor tissue. It is

~$400–$800/mo

Platinum-Based Chemotherapy Agent

Carboplatin (brand: Paraplatin) is a second-generation platinum chemotherapy used in combination regimens for

~$50–$500/cycle

Nitrosourea Alkylating Agent

Carmustine (brand: BiCNU) is a nitrosourea alkylating agent that crosses the blood-brain barrier, making it va

~$500–$2,000/cycle

Platinum-Based Chemotherapy Agent

Cisplatin is a foundational platinum-based chemotherapy agent used in combination regimens for many cancer typ

~$30–$300/cycle

Anti-CD38 Monoclonal Antibody

Darzalex (daratumumab) is an anti-CD38 monoclonal antibody by Janssen approved for multiple myeloma in multipl

~$10,000–$15,000/mo

Erythropoiesis-Stimulating Agent (ESA)

Darbepoetin Alfa

darbepoetin alfa

Darbepoetin alfa (brand: Aranesp) is an erythropoiesis-stimulating agent (ESA) used to treat anemia caused by

Anthracycline / Antitumor Antibiotic

Doxorubicin Hydrochloride

doxorubicin hydrochloride

Doxorubicin hydrochloride (brand: Adriamycin) is a foundational anthracycline chemotherapy used in combination

~$100–$500/cycle

PD-L1 Immune Checkpoint Inhibitor

Imfinzi (durvalumab) is a PD-L1 checkpoint inhibitor by AstraZeneca approved for unresectable Stage III NSCLC

HER2-Targeted ADC — Topoisomerase I In

fam-trastuzumab deruxtecan-nxki

Enhertu (fam-trastuzumab deruxtecan-nxki, T-DXd) is a HER2-targeted ADC by AstraZeneca/Daiichi Sankyo that has

~$18,000–$22,000/mo

Androgen Receptor Inhibitor

Xtandi (enzalutamide) is an androgen receptor inhibitor by Astellas/Pfizer approved for castration-resistant p

~$18,000–$20,000/mo

Androgen Receptor Inhibitor

Erleada (apalutamide) is an androgen receptor inhibitor by Janssen approved for non-metastatic castration-resi

Everolimus (brand: Afinitor) is an mTOR inhibitor by Novartis with multiple FDA-approved oncology indications

Aromatase Inactivator / Steroidal Arom

Exemestane (brand: Aromasin) is a steroidal aromatase inactivator used in the adjuvant treatment of postmenopa

Nucleoside Antimetabolite / Chemothera

gemcitabine hydrochloride

Gemcitabine is a nucleoside antimetabolite chemotherapy agent used as monotherapy or in combination regimens f

~$100–$600/cycle

BCR-ABL / KIT / PDGFR Tyrosine Kinase

imatinib mesylate

Gleevec (imatinib mesylate) was the first targeted oncology therapy to transform cancer treatment, dramaticall

~$200–$2,000/mo

Immune Response Modifier / Toll-Like R

Imiquimod Cream 5%

Imiquimod 5% cream (brand: Aldara) is an immune response modifier that activates innate immune responses throu

CD22-Targeted Antibody-Drug Conjugate

inotuzumab ozogamicin

Besponsa (inotuzumab ozogamicin) is a CD22-targeted antibody-drug conjugate by Pfizer approved for adults with

~$20,000–$25,000/cycle

CTLA-4 Immune Checkpoint Inhibitor

Yervoy (ipilimumab) is a CTLA-4 checkpoint inhibitor by Bristol Myers Squibb. It is the first checkpoint inhib

~$35,000–$60,000/course

HER2-Targeted Antibody-Drug Conjugate

ado-trastuzumab emtansine

Kadcyla (ado-trastuzumab emtansine, T-DM1) is an antibody-drug conjugate (ADC) by Genentech combining trastuzu

PD-1 Immune Checkpoint Inhibitor

Keytruda (pembrolizumab) is a PD-1 immune checkpoint inhibitor manufactured by Merck. It is one of the most wi

~$11,000–$14,000/mo

PD-1 Immune Checkpoint Inhibitor (Subc

pembrolizumab / berahyaluronidase alfa-pmph

Keytruda Qlex is a subcutaneous formulation of pembrolizumab co-formulated with berahyaluronidase alfa-pmph. I

Immunomodulatory Agent (IMiD) / Cerebl

Revlimid (lenalidomide) is an immunomodulatory agent (IMiD) approved for multiple myeloma, MDS with del(5q), f

~$500–$16,000/mo

Tumor-Infiltrating Lymphocyte (TIL) Th

Lifileucel (brand: Amtagvi) is the first FDA-approved tumor-infiltrating lymphocyte (TIL) therapy, approved fo

~$515,000 one-time

Lynparza (olaparib) is a PARP inhibitor by AstraZeneca approved for multiple cancers associated with BRCA muta

Alkylating Agent / Nitrogen Mustard

Melphalan (brand: Alkeran) is a nitrogen mustard alkylating agent used to treat multiple myeloma and ovarian c

Antitumor Antibiotic / Alkylating Agen

Mitomycin is an antitumor antibiotic chemotherapy agent with alkylating properties. It is used intravenously i

Taxane / Microtubule Stabilizer (Album

paclitaxel protein-bound particles for injectabl

Nab-paclitaxel (paclitaxel protein-bound) is an albumin-bound formulation of paclitaxel that does not require

Nucleoside Metabolic Inhibitor / Purin

Nelarabine (brand: Arranon) is a purine nucleoside analog used for the treatment of relapsed or refractory T-c

PD-1 Immune Checkpoint Inhibitor

Opdivo (nivolumab) is a PD-1 immune checkpoint inhibitor by Bristol Myers Squibb approved for over 15 tumor ty

~$10,000–$13,000/mo

Third-Generation EGFR Inhibitor

osimertinib mesylate

Tagrisso (osimertinib) is a third-generation, CNS-penetrant EGFR inhibitor by AstraZeneca approved as first-li

~$22,000–$24,000/mo

Platinum-Based Chemotherapy Agent

Oxaliplatin (brand: Eloxatin) is a third-generation platinum chemotherapy agent that is a cornerstone of color

~$200–$1,500/cycle

CDK4/6 Inhibitor

Ibrance (palbociclib) is a CDK4/6 inhibitor by Pfizer approved for HR-positive, HER2-negative advanced or meta

~$18,000–$20,000/mo

5-HT3 Receptor Antagonist / Antiemetic

palonosetron hydrochloride

Aloxi (palonosetron HCl) is a second-generation 5-HT3 receptor antagonist with a longer half-life than older a

Bisphosphonate / Osteoclast Inhibitor

Pamidronate Disodium

pamidronate disodium

Pamidronate disodium (brand: Aredia) is a bisphosphonate used to treat hypercalcemia of malignancy, bone metas

Antifolate / Multitargeted Antimetabol

pemetrexed disodium

Pemetrexed (brand: Alimta) is a multitargeted antifolate chemotherapy approved for non-squamous non-small cell

HER2 Dimerization Inhibitor

Perjeta (pertuzumab) is a HER2 dimerization inhibitor by Genentech/Roche used with trastuzumab and chemotherap

~$4,000–$7,000/cycle

CDK4/6 Inhibitor

ribociclib succinate

Kisqali (ribociclib) is a CDK4/6 inhibitor by Novartis for HR+/HER2-negative advanced or metastatic breast can

~$17,000–$21,000/mo

Anti-CD20 Monoclonal Antibody

Rituxan (rituximab) is an anti-CD20 monoclonal antibody that is foundational in the treatment of B-cell non-Ho

~$3,000–$8,000/infusion

Pegylated Interferon Alfa / JAK-STAT P

ropeginterferon alfa-2b-njft

Besremi (ropeginterferon alfa-2b-njft) is a long-acting pegylated interferon alfa approved for adults with pol

~$8,000–$12,000/mo

Bispecific Antibody — EGFR × MET

amivantamab-vmjw

Rybrevant (amivantamab-vmjw) is a bispecific antibody targeting EGFR and MET by Janssen. It is FDA-approved fo

Bispecific Antibody — EGFR × MET (Subc

amivantamab and hyaluronidase-lpuj

Rybrevant SC (amivantamab and hyaluronidase-lpuj) is the subcutaneous formulation of amivantamab co-formulated

TCR-T Cell Therapy — MAGE-A4 Directed

afamitresgene autoleucel

Tecelra (afamitresgene autoleucel, afami-cel) is the first FDA-approved TCR-T cell therapy, indicated for HLA-

~$727,000 one-time

PD-L1 Immune Checkpoint Inhibitor

Tecentriq (atezolizumab) is a PD-L1 immune checkpoint inhibitor manufactured by Genentech/Roche. It works diff

PD-L1 Immune Checkpoint Inhibitor (Sub

Tecentriq Hybreza

atezolizumab / hyaluronidase-tqjs

Tecentriq Hybreza is a subcutaneous formulation combining atezolizumab with hyaluronidase-tqjs. It delivers th

HER2-Targeted Monoclonal Antibody

Herceptin (trastuzumab) is a HER2-targeted monoclonal antibody by Genentech/Roche, foundational in the treatme

~$5,000–$8,000/mo

Antineoplastic Agent — Arsenic Compoun

arsenic trioxide

Trisenox (arsenic trioxide) is an antineoplastic agent used in combination with all-trans retinoic acid (ATRA)

BCL-2 Inhibitor

Venclexta (venetoclax) is a BCL-2 inhibitor by AbbVie/Genentech approved for CLL/SLL (with obinutuzumab or rit

~$20,000–$25,000/mo

CDK4/6 Inhibitor

Verzenio (abemaciclib) is a CDK4/6 inhibitor by Eli Lilly approved for hormone receptor-positive (HR+), HER2-n

Hypomethylating Agent (HMA) / DNA Meth

Vidaza (azacitidine) is a hypomethylating agent (HMA) used in the treatment of myelodysplastic syndromes (MDS)

CAR-T Cell Therapy — CD19-directed

axicabtagene ciloleucel

Yescarta (axicabtagene ciloleucel) is an anti-CD19 CAR-T cell therapy by Kite Pharma (Gilead). It is FDA-appro

~$425,000 one-time

Prior Authorization

We handle the full PA process — clinical docs, peer-to-peer, and appeals — at no cost.

Prior Auth Guide →

Patient Assistance

Free medication for uninsured/underinsured patients. We assess eligibility and enroll at no charge.

Patient Assistance →

Medication Cost

WAC list prices, coverage notes, and guidance on reducing out-of-pocket costs.

Specialty Delivery

Temperature-monitored cold-chain delivery with tracking to all 50 states.

Delivery Info →

Disclaimer: Educational purposes only. Not medical advice. WAC prices approximate from public sources as of 2025-2026. Actual cost varies by insurance, prior authorization, and patient assistance. Last reviewed: September 2026 — BiologicHealthPlus Clinical Team.